Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003396 · ClinicalTrials.gov registry record · Phase 2
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
A Phase 2 study, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00003396: Completed Phase 2 study, sponsored by University of Maryland, Baltimore.
NCT00003396 is a Phase 2 study that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 42 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003396, a Phase 2 study, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation from related donors to prevent graft-versus-host disease in treating patients with hematologic cancer.
Interventions
- DRUG cyclophosphamide
- DRUG melphalan
- PROCEDURE peripheral blood stem cell transplantation
- BIOLOGICAL anti-thymocyte globulin
- BIOLOGICAL graft-versus-tumor induction therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 1998-09 |
| Est. Completion | 2002-12 |
| Phase | Phase 2 |
What the finished NCT00003396 record still lists
NCT00003396 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 42 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.
NCT00003396 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003396 about?
NCT00003396 is a clinical study titled "Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer". RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of peripheral stem cell transplantation from related donors to prevent graft-vers...
What is the current status of trial NCT00003396?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 1998-09. Estimated completion is 2002-12.
What interventions are being tested in trial NCT00003396?
The interventions under investigation include: cyclophosphamide (DRUG), melphalan (DRUG), peripheral blood stem cell transplantation (PROCEDURE), anti-thymocyte globulin (BIOLOGICAL), graft-versus-tumor induction therapy (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003396?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003396's enrollment target sits among peer trials
42 1339th of 2000 higher than 649 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia